Role of curcumin in prevention of cisplatin-induced nephrotoxicity in rat
Abstract
Cisplatin is a platinum anticancer drug approved by the FDA in 1978. It is used to treat a broad spectrum of malignancies but the amount of drug necessary to produce a significant reduction in tumor burden usually produces significant nephrotoxicity. the purpose of this study was to evaluate the role of curcumin in the prevention of cisplatin-induced nephrotoxicity in rats. Thirty male albino rats weighing (200-250 gm), they were equally divided into three groups: Normal group (Isotonic saline group), control group "Cisplatin group" (12 mg/kg cisplatin, single dose I.P.) and curcumin group (50 mg/kg I.P.) prophylactically one day prior to cisplatin administration and continued for further 3 days. Cisplatin administration resulted in a significant increase in serum creatinine, BUN and MDA while serum glutathione level was significantly decrease compared to that of normal group. The Sections of kidneys rats treated by cisplatin were showed degenerative and necrosis of the proximal and distal convoluted tubules. Curcumin administration resulted in a significant decrease in serum creatinine, BUN and serum MDA while serum glutathione level was to be significantly increased. There were very minimal degenerative changes in kidney tissues of rats comparing to that of control group.
Metrics